ISCT 2021 | Improving patient access to cell & gene therapies

Miguel Forte, MD, PhD, Bone Therapeutics SA, Gosselies, Belgium, discusses some of the key recent developments and remaining challenges in the commercialisation of cell and gene therapy (CGT) products. Dr Forte highlights that although CGT products offer transformative long-term benefits to patients via complex mechanisms, patient access remains limited due to difficulties in their characterization, manufacture and distribution. Due to the potential curative nature of these therapies, it will also be necessary to implement new mechanisms of payment and reimbursement. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.